Norovirus Infections, Norwalk Gastroenteritis
Conditions
Brief summary
A total of 450 subjects were enrolled, divided into four age groups, including 18-59 years, 6-17 years, 3-5 years, and 6-35 months. There are three types of the test vaccine component in each age group. A total of 30 people in each dose group were vaccinated with the test vaccine or placebo 1 or placebo 2, respectively, in a ratio of 3: 1: 1. The 18-59-year-old, 6-17-year-old, and 3-5-year-old age groups were vaccinated 2 times at a time interval of 28 days. The 6-35 month age group is divided into two groups, Group 1 is inoculated with 2 doses interval of 28 days each, and Group 2 is inoculated with 3 doses interval of 28 days.
Detailed description
From January to April 2020, this study was affected by the COVID-19 epidemic, which caused the two groups（6-17-year-old，3-5-year-old） of subjects to vaccinate beyond the window and deviate from the experimental plan. After communication between the researcher, the sponsor and the statistician, it was decided to restart the Phase I clinical trials of these two groups.
Interventions
BIOLOGICALNorovirus Bivalent (GI.1 / GII.4) Vaccine（low）
Norovirus Bivalent (GI.1 / GII.4) Vaccine（low）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
BIOLOGICALNorovirus Bivalent (GI.1 / GII.4) Vaccine（middle）
Norovirus Bivalent (GI.1 / GII.4) Vaccine（middle）administered intramuscularly according to a 0, 28，（56） day vaccination schedule
BIOLOGICALNorovirus Bivalent (GI.1 / GII.4) Vaccine（high）
Norovirus Bivalent (GI.1 / GII.4) Vaccine（high）administered intramuscularly according to a 0, 28，（56）day vaccination schedule
BIOLOGICALNormal saline
Normal saline administered intramuscularly according to a 0, 28 ，（56）day vaccination schedule
BIOLOGICALAluminum adjuvant
Aluminum adjuvant administered intramuscularly according to a 0, 28，（56） day vaccination schedule
Sponsors
Lanzhou Institute of Biological Products Co., Ltd
Beijing Zhong Sheng Heng Yi Pharmaceutical Technology Co., Ltd.
Zhengzhou University
National Vaccine and Serum Institute, China
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
6 Months to 59 Years
Healthy volunteers
Yes
Inclusion criteria
* Aged 6 months to 59 years old, can provide legal identification of Chinese population; * Based on medical history and physical examination, determined by the researcher as healthy; * Volunteer legal guardians or trustees have the ability to understand (non-illiterate) research procedures, sign informed consent voluntarily with informed consent, and be able to comply with the requirements of clinical research protocols; * Female subjects of childbearing age were not pregnant at the time of enrollment (negative urine pregnancy test), were not breastfeeding, and had no birth plan within the first 3 months after enrollment; effective contraceptive measures were taken within 2 weeks before enrollment.
Exclusion criteria
* Axillary body temperature before inoculation on the day of entry\> 37.0 ℃; * Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc .; * Have a history of epilepsy, convulsions or convulsions, or a family history of mental illness; * Those who received immunoenhancement or inhibitor therapy within months (continuous oral or instillation for more than 14 days); * Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases; * No spleen or spleen function defect caused by any situation; * Severe liver and kidney disease, drug-uncontrollable hypertension (systolic blood pressure\> 140mmHg, diastolic blood pressure\> 90mmHg), diabetic complications, malignant tumors, various acute diseases or chronic attacks of acute diseases; * Have a history of chronic gastrointestinal diseases, diarrhea or other digestive system diseases, and have had gastroenteritis requiring treatment in the past 7 days;. * Have a history of abnormal coagulation function (such as coagulation factor deficiency, coagulopathy); * Have a history of severe allergic reactions to vaccination; are allergic to any component of the test vaccine; * Live attenuated vaccine within14 days; other vaccines received within 7 days; * Participating in other clinical trials in the near future; * The investigator judges other circumstances that are not suitable for participation in this clinical trial. In addition to the general
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All SAEs within 6 months after the last dose is vaccinated | 6 months | — |
| AE of local and systemic reactions within 30 minutes after each dose | 30 minutes | — |
| All active AEs within 0-7 days after each dose | 7 days | Active AE: Local and systemic adverse reactions occurring within 0-7 days after each dose of vaccination |
| All non-active collection AEs within 0-28（30） days after each dose | 28（30） days | Adverse events other than active AE include solicitation adverse events reported in addition to the specified solicitation time window |
Secondary
| Measure | Time frame |
|---|---|
| Calculate geometric mean titer (GMT) of NoV GI.1 and GII.4 IgG antibodies | 28 days after the full vaccination |
| Calculate positive rate of NoV GI.1 and GII.4 IgG antibodies | 28 days after the full vaccination |
| Calculate NoV GI.1 and GII.4 HBGA-blocking antibody titers | 28 days after the full vaccination |
| Calculate NoV GI.1 and GII.4 HBGA-blocking antibody positive rates | 28 days after the full vaccination |
Countries
China
Outcome results
None listed